...
机译:NCCTG N0879(联盟):Carboplatin,紫杉醇和Bevacizumab的随机阶段2合作组试验?±everolimus用于转移性黑色素瘤
Division of Medical OncologyMayo ClinicRochester Minnesota;
Alliance Statistics and Data CenterMayo ClinicRochester Minnesota;
Department of MedicineMayo ClinicRochester Minnesota;
Minnesota OncologyCoon RapidsMinnesota;
Division of Medical OncologyMayo ClinicRochester Minnesota;
Division of Molecular GeneticsMayo ClinicRochester Minnesota;
Division of Anatomic PathologyMayo ClinicRochester Minnesota;
Division of Hematology/Oncology Mayo Clinic in ArizonaScottsdale Arizona;
Division of Hematology/Oncology Mayo Clinic in FloridaJacksonville Florida;
Division of Medical OncologyMayo ClinicRochester Minnesota;
Unity Hospital Metro Minnesota Community Oncology Research ConsortiumSaint Louis Park Minnesota;
Sanford Clinic North‐FargoFargo North Dakota;
Division of Medical OncologyMayo ClinicRochester Minnesota;
chemotherapy; everolimus; melanoma; uveal;
机译:NCCTG N0879(联盟):Carboplatin,紫杉醇和Bevacizumab的随机阶段2合作组试验?±everolimus用于转移性黑色素瘤
机译:比较贝伐单抗加卡铂和紫杉醇与单独使用卡铂和紫杉醇在先前未经治疗的局部晚期或转移性非小细胞肺癌中的随机第二阶段试验。
机译:CALGB 40502 / NCCTG N063H:每周一次紫杉醇(P)与每周一次纳米粒白蛋白结合的纳布-紫杉醇(NP)或伊沙贝比隆(Ix)进行或不使用贝伐单抗(B)作为局部复发或转移性一线治疗的随机III期试验乳腺癌(MBC)
机译:I / II期临床试验关于每周紫杉醇(WPTX)和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
机译:贝叶斯方法在I期试验和小型N顺序多分配随机试验
机译:NCCTG N0879(联盟):卡铂紫杉醇贝伐单抗+ /-依维莫司(CPB +/-)用于转移性黑色素瘤的II期随机合作组试验
机译:亚血管血管在转移性恶性黑色素瘤中的II期研究(NCCTG-N0377,联盟)